IL198182A0 - Use of citrulline for treating undernutrition conditions - Google Patents

Use of citrulline for treating undernutrition conditions

Info

Publication number
IL198182A0
IL198182A0 IL198182A IL19818209A IL198182A0 IL 198182 A0 IL198182 A0 IL 198182A0 IL 198182 A IL198182 A IL 198182A IL 19818209 A IL19818209 A IL 19818209A IL 198182 A0 IL198182 A0 IL 198182A0
Authority
IL
Israel
Prior art keywords
citrulline
treating
undernutrition
conditions
undernutrition conditions
Prior art date
Application number
IL198182A
Other languages
English (en)
Original Assignee
Univ Rene Descartes Paris V Of
Biocodex Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rene Descartes Paris V Of, Biocodex Of filed Critical Univ Rene Descartes Paris V Of
Publication of IL198182A0 publication Critical patent/IL198182A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL198182A 2006-10-17 2009-04-16 Use of citrulline for treating undernutrition conditions IL198182A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0609077A FR2907011B1 (fr) 2006-10-17 2006-10-17 Utilisation de la citrulline pour le traitement des etats de denutrition
PCT/FR2007/001407 WO2008049984A2 (fr) 2006-10-17 2007-08-29 Utilisation de la citrulline pour le traitement des etats de denutrition

Publications (1)

Publication Number Publication Date
IL198182A0 true IL198182A0 (en) 2009-12-24

Family

ID=37888135

Family Applications (1)

Application Number Title Priority Date Filing Date
IL198182A IL198182A0 (en) 2006-10-17 2009-04-16 Use of citrulline for treating undernutrition conditions

Country Status (8)

Country Link
US (1) US20100298437A1 (enExample)
EP (1) EP2081564B1 (enExample)
JP (1) JP2010506887A (enExample)
CN (1) CN101605538A (enExample)
CA (1) CA2666538A1 (enExample)
FR (1) FR2907011B1 (enExample)
IL (1) IL198182A0 (enExample)
WO (1) WO2008049984A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913885B1 (fr) * 2007-03-22 2012-07-20 Univ Paris Descartes Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
DE102007016715A1 (de) * 2007-04-04 2008-10-09 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
FR2970414B1 (fr) 2011-01-14 2013-03-22 Univ Paris Descartes Action preventive de la citrulline sur le developpement spontane des tumeurs
EP3021690B1 (en) 2013-06-10 2017-05-17 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
FR3009963B1 (fr) 2013-09-03 2017-03-03 Biolis Composition de lutte contre les troubles de la locomotion
EP2875736B1 (en) 2013-11-26 2016-07-27 Citrage N-Carbamoylputrescine to enhance muscle protein synthesis
WO2015137387A1 (ja) * 2014-03-11 2015-09-17 協和発酵バイオ株式会社 筋肉増強剤
CN104263550A (zh) * 2014-09-11 2015-01-07 滁州斯迈特复合材料有限公司 化妆液玻璃瓶清洁剂
ES2798772T3 (es) * 2015-09-04 2020-12-14 Univ Tsukuba Composición para el desarrollo muscular y método para desarrollar músculo
KR102396603B1 (ko) 2015-09-16 2022-05-11 원광대학교산학협력단 시트룰린을 유효성분으로 함유하는 간 기능 개선용 조성물
CN108473384A (zh) 2015-10-27 2018-08-31 细胞酶动物营养品公司 动物营养成分及相关方法
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
AU2018415594B2 (en) 2018-03-27 2024-10-10 N.V. Nutricia Insulin control in overweight or obese adult during life time intervention
CN118248029A (zh) * 2024-03-21 2024-06-25 江南大学 一种月球环境下的仿生结肠发酵系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6305M (enExample) * 1966-12-15 1968-09-16
FR6304M (enExample) * 1966-12-15 1968-09-16
FR6306M (enExample) * 1966-12-15 1968-09-16
US5189025A (en) * 1988-12-09 1993-02-23 Board Of Regenets, The University Of Texas System Methods for the treatment of malignant disease in patients using citrulline containing amino acid solutions
US4988724A (en) * 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
FR2691359B1 (fr) * 1992-05-20 1995-06-23 Krempf Michel Nouvelle application therapeutique du malate de 1-citrulline.
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
FR2857262B1 (fr) * 2003-07-08 2007-10-05 Biocodex Lab Utilisation de la citrulline dans le cadre de l'insuffisance intestinale

Also Published As

Publication number Publication date
EP2081564A2 (fr) 2009-07-29
US20100298437A1 (en) 2010-11-25
EP2081564B1 (fr) 2014-01-01
CA2666538A1 (fr) 2008-05-02
FR2907011A1 (fr) 2008-04-18
CN101605538A (zh) 2009-12-16
WO2008049984A2 (fr) 2008-05-02
FR2907011B1 (fr) 2010-05-14
JP2010506887A (ja) 2010-03-04
WO2008049984A3 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
GB2439393B (en) Cannabinoids for use in the treatment of neuropathic pain
IL194202A0 (en) Treatment using citrulline
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
IL193460A0 (en) Compounds and methods for treatment of stroke
GB0610867D0 (en) Treatment of pain
IL202015A0 (en) Methods and compositions for treating skin conditions
PT2397142T (pt) Utilizações de inibidores da dpp iv
IL194820A0 (en) Devices and methods for treatment of tissue
IL205318A0 (en) Compositions comprising electrochemically altered aqueous fluids and uses thereof for treating inflammation
EP2032131A4 (en) Methods of Treatment
IL193748A0 (en) Treatment of pain
IL207292A0 (en) Use of ranolazine for treating pain
ZA200900140B (en) Methods and compositions for treating biofilms
EP2205236A4 (en) NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS
IL198723A0 (en) Methods and compositions for therapeutic treatment
EP2395980A4 (en) COMPOSITIONS AND METHODS FOR TREATING POST-OPERATIVE PAIN WITH BUPIVACAINE AND AN ANTI-INFLAMMATORY AGENT
IL243294A0 (en) Compounds and compositions for the treatment of cancer
ZA200806808B (en) Treatment of stressed patients
IL202307A0 (en) Multikinase inhibitors for use in the treatment of cancer
GB0909297D0 (en) Composition for the treatment of skin conditions
ZA200807357B (en) Inhibitors of PAI-1 for treatment of muscular conditions
GB0718918D0 (en) Compositions and methods for treating skin conditions
GB0610746D0 (en) Method of treatment
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
IL194066A0 (en) Therapeutic composition for treatment of tinnitus